10 completed, 3 terminated, 1 withdrawn. 6 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 6 | Completed 3, Terminated 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow laquinimod: new trials by email Literature Review of laquinimod trials Research Report on laquinimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Laquinimod Eye-drops in Healthy Participants Laquinimod, Placebo - Eye Diseases | Phase 1 | Completed | Active Biotech AB | 54 | 2021-12-09 | 2023-01-31 |
| A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo Placebo, Laquinimod - Primary Progressive Multiple Sclerosis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 374 | 2015-01-12 | 2022-03-10 |
| A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod Laquinimod, Placebo - Huntington's Disease | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 352 | 2014-10-28 | 2020-05-04 |
| A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together laquinimod, Placebo - Pharmacokinetics, Pharmacodynamics | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 40 | 2014-02-01 | 2021-11-09 |
| A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Laquinimod, Avonex® - Relapsing Remitting Multiple Sclerosis | Phase 3 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-01-01 | 2021-11-09 | |
| The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Laquinimod, Placebo - Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 2199 | 2013-02-20 | 2021-11-09 |
| A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis Laquinimod, Placebo - Lupus Arthritis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 82 | 2010-10-04 | 2022-07-07 |
| A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone - Lupus Nephritis | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 46 | 2010-09-01 | 2022-03-09 |
| A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis Laquinimod - Relapsing Multiple Sclerosis | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1047 | 2010-05-27 | 2021-12-09 |
| Laquinimod Phase IIa Study in Active Crohn's Disease Laquinimod, placebo - Crohn's Disease | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 180 | 2010-05-01 | 2015-03-20 |
| A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course Laquinimod - Relapsing Multiple Sclerosis | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 839 | 2009-11-10 | 2021-12-09 |
| BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) Laquinimod, Placebo, Avonex® - Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1331 | 2008-04-24 | 2022-04-21 |
| Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) Laquinimod, Placebo - Multiple Sclerosis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1106 | 2007-11-13 | 2021-11-02 |
| An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease Laquinimod, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Teva Pharmaceutical Industries, Ltd. | 257 | 2005-12-07 | 2019-03-27 |
Multiple Sclerosis (4) · Lupus Erythematosus, Systemic (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Crohn Disease (1) · Eye Diseases (1) · Huntington Disease (1) · Lupus Nephritis (1) · Multiple Sclerosis, Chronic Progressive (1) · Recurrence (1)
Teva Branded Pharmaceutical Products R&D, Inc. (12) · Active Biotech AB (1) · Teva Pharmaceutical Industries, Ltd. (1)
Germany (9) · Italy (9) · Russia (9) · Spain (9) · United States (9) · Poland (8) · United Kingdom (8) · Canada (7) · Czechia (7) · Israel (7) · Ukraine (6) · Bulgaria (5) · Estonia (5) · France (5) · Georgia (5)
Giancarlo Comi (2) · Geert D'Haens, MD PhD (1) · Giancarlo Comi, Prof., MD (1) · Prof. Timothy Vollmer, MD (1)
PMID 26000222, PMID 36163349, PMID 22417253, PMID 24029546, PMID 25281416, PMID 27296315, PMID 32651286, PMID 34378456, PMID 38280392
2009 (2), 2014 (2), 2005 (1)